# A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors

> **NCT05110807** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 38 (estimated)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** TQB3617

## Key facts

- **NCT ID:** NCT05110807
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-05
- **Primary completion:** 2022-10
- **Final completion:** 2022-12
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2022-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05110807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05110807, "A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05110807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*